Global Pulmonary Arterial Hypertension (PAH) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 147486
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 130
  • list Pharmaceuticals and Healthcare

Pulmonary hypertension is a condition of increased blood pressure within the arteries of the lungs.[6] Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat.

Scope of the Report:

This report focuses on the Pulmonary Arterial Hypertension (PAH) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Pulmonary Arterial Hypertension (PAH) is expected to grow at a CAGR of roughly 6.1% over the next five years, will reach 8510 million US$ in 2023, from 5960 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Actelion

Gilead Sciences

United Therapeutics

GlaxoSmithKline

Pfizer

Bayer

Arena

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Prostacyclin and Prostacyclin Analogs

SGC Stimulators

ERA

PDE-5

Market Segment by Applications, can be divided into

Hospital

Clinic

There are 15 Chapters to deeply display the global Pulmonary Arterial Hypertension (PAH) market.

Chapter 1, to describe Pulmonary Arterial Hypertension (PAH) Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Pulmonary Arterial Hypertension (PAH), with sales, revenue, and price of Pulmonary Arterial Hypertension (PAH), in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Pulmonary Arterial Hypertension (PAH), for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Pulmonary Arterial Hypertension (PAH) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Pulmonary Arterial Hypertension (PAH) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Pulmonary Arterial Hypertension (PAH) Introduction

1.2 Market Analysis by Type

1.2.1 Prostacyclin and Prostacyclin Analogs

1.2.2 SGC Stimulators

1.2.3 ERA

1.2.4 PDE-5

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinic

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Actelion

2.1.1 Business Overview

2.1.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Gilead Sciences

2.2.1 Business Overview

2.2.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 United Therapeutics

2.3.1 Business Overview

2.3.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 GlaxoSmithKline

2.4.1 Business Overview

2.4.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Pfizer

2.5.1 Business Overview

2.5.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Bayer

2.6.1 Business Overview

2.6.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Arena

2.7.1 Business Overview

2.7.2 Pulmonary Arterial Hypertension (PAH) Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Arena Pulmonary Arterial Hypertension (PAH) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Pulmonary Arterial Hypertension (PAH) Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Pulmonary Arterial Hypertension (PAH) Manufacturer Market Share in 2017

3.3.2 Top 6 Pulmonary Arterial Hypertension (PAH) Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Pulmonary Arterial Hypertension (PAH) Market Analysis by Regions

4.1 Global Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Regions

4.1.1 Global Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Regions (2013-2018)

4.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Regions (2013-2018)

4.2 North America Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

4.3 Europe Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

4.5 South America Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

5 North America Pulmonary Arterial Hypertension (PAH) by Countries

5.1 North America Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Countries

5.1.1 North America Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Countries (2013-2018)

5.1.2 North America Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Countries (2013-2018)

5.2 United States Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

5.3 Canada Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

5.4 Mexico Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

6 Europe Pulmonary Arterial Hypertension (PAH) by Countries

6.1 Europe Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Countries

6.1.1 Europe Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Countries (2013-2018)

6.2 Germany Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

6.3 UK Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

6.4 France Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

6.5 Russia Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

6.6 Italy Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

7 Asia-Pacific Pulmonary Arterial Hypertension (PAH) by Countries

7.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Countries (2013-2018)

7.2 China Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

7.3 Japan Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

7.4 Korea Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

7.5 India Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

8 South America Pulmonary Arterial Hypertension (PAH) by Countries

8.1 South America Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Countries

8.1.1 South America Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Countries (2013-2018)

8.1.2 South America Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

8.3 Argentina Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

8.4 Colombia Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

9 Middle East and Africa Pulmonary Arterial Hypertension (PAH) by Countries

9.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

9.3 UAE Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

9.4 Egypt Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

9.5 Nigeria Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

9.6 South Africa Pulmonary Arterial Hypertension (PAH) Sales and Growth Rate (2013-2018)

10 Global Pulmonary Arterial Hypertension (PAH) Market Segment by Type

10.1 Global Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Pulmonary Arterial Hypertension (PAH) Sales and Market Share by Type (2013-2018)

10.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue and Market Share by Type (2013-2018)

10.2 Prostacyclin and Prostacyclin Analogs Sales Growth and Price

10.2.1 Global Prostacyclin and Prostacyclin Analogs Sales Growth (2013-2018)

10.2.2 Global Prostacyclin and Prostacyclin Analogs Price (2013-2018)

10.3 SGC Stimulators Sales Growth and Price

10.3.1 Global SGC Stimulators Sales Growth (2013-2018)

10.3.2 Global SGC Stimulators Price (2013-2018)

10.4 ERA Sales Growth and Price

10.4.1 Global ERA Sales Growth (2013-2018)

10.4.2 Global ERA Price (2013-2018)

10.5 PDE-5 Sales Growth and Price

10.5.1 Global PDE-5 Sales Growth (2013-2018)

10.5.2 Global PDE-5 Price (2013-2018)

11 Global Pulmonary Arterial Hypertension (PAH) Market Segment by Application

11.1 Global Pulmonary Arterial Hypertension (PAH) Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinic Sales Growth (2013-2018)

12 Pulmonary Arterial Hypertension (PAH) Market Forecast (2018-2023)

12.1 Global Pulmonary Arterial Hypertension (PAH) Sales, Revenue and Growth Rate (2018-2023)

12.2 Pulmonary Arterial Hypertension (PAH) Market Forecast by Regions (2018-2023)

12.2.1 North America Pulmonary Arterial Hypertension (PAH) Market Forecast (2018-2023)

12.2.2 Europe Pulmonary Arterial Hypertension (PAH) Market Forecast (2018-2023)

12.2.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Forecast (2018-2023)

12.2.4 South America Pulmonary Arterial Hypertension (PAH) Market Forecast (2018-2023)

12.2.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Forecast (2018-2023)

12.3 Pulmonary Arterial Hypertension (PAH) Market Forecast by Type (2018-2023)

12.3.1 Global Pulmonary Arterial Hypertension (PAH) Sales Forecast by Type (2018-2023)

12.3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share Forecast by Type (2018-2023)

12.4 Pulmonary Arterial Hypertension (PAH) Market Forecast by Application (2018-2023)

12.4.1 Global Pulmonary Arterial Hypertension (PAH) Sales Forecast by Application (2018-2023)

12.4.2 Global Pulmonary Arterial Hypertension (PAH) Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Pulmonary Arterial Hypertension (PAH) Picture

Table Product Specifications of Pulmonary Arterial Hypertension (PAH)

Figure Global Sales Market Share of Pulmonary Art

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery